Amivantamab – July 2026

  • Brand names:
    • Rybrevant SC®
  • Pharmaceutical Company:
    • JANSSEN-CILAG PTY LTD
  • Condition/Indication: Non-small cell lung cancer (NSCLC)
  • Meeting Date: July 2026
Public Summary Documents
Last updated
13 November 2026